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ABSTRACT
Allosteric agonists are powerful tools for exploring the pharma-
cology of closely related G protein-coupled receptors that have
nonselective endogenous ligands, such as the short chain fatty
acids at free fatty acid receptors 2 and 3 (FFA2/GPR43 and
FFA3/GPR41, respectively). We explored the molecular mech-
anisms mediating the activity of 4-chloro--(1-methylethyl)-N-
2-thiazolylbenzeneacetamide (4-CMTB), a recently described
phenylacetamide allosteric agonist and allosteric modulator of
endogenous ligand function at human FFA2, by combining our
previous knowledge of the orthosteric binding site with targeted
examination of 4-CMTB structure-activity relationships and
mutagenesis and chimeric receptor generation. Here we show
that 4-CMTB is a selective agonist for FFA2 that binds to a site
distinct from the orthosteric site of the receptor. Ligand struc-
ture-activity relationship studies indicated that the N-thiazolyl
amide is likely to provide hydrogen bond donor/acceptor inter-
actions with the receptor. Substitution at Leu173 or the ex-
change of the entire extracellular loop 2 of FFA2 with that of
FFA3 was sufficient to reduce or ablate, respectively, allosteric
communication between the endogenous and allosteric ago-
nists. Thus, we conclude that extracellular loop 2 of human
FFA2 is required for transduction of cooperative signaling be-
tween the orthosteric and an as-yet-undefined allosteric bind-
ing site of the FFA2 receptor that is occupied by 4-CMTB.
Introduction
Many G protein-coupled receptors (GPCRs) share either
the same endogenous ligand or respond to a group of ligands
with overlapping selectivity, making efforts to ascribe indi-
vidual biology particularly challenging. This is especially
problematic when the “orthosteric” binding pocket for endog-
enous ligands is very highly conserved between receptor sub-
types, thereby limiting selectivity at these GPCRs. Selectiv-
ity issues at related GPCRs have been circumvented by the
use of “allosteric” ligands, which, as their name suggests,
bind to a distinct or “other” site on the receptor (Christopou-
los, 2002; Kenakin, 2009; Smith and Milligan, 2010; Smith et
al., 2011). Thought to have been under less evolutionary
pressure to remain conserved (Soudijn et al., 2004), allosteric
binding sites provide a novel means of selectively regulating
and therefore functionally characterizing related GPCRs.
This work was supported by The Welcome Trust [Grant 089600/Z/09/Z] (to G.M.)
and an Australian C.J. Martin National Health and Medical Research Council and
National Heart Foundation Overseas Research Fellowship (to N.J.S.).
Current affiliation for Nicola J. Smith: Molecular Cardiology Group, Victor
Chang Cardiac Research Institute, Darlinghurst, Sydney, Australia. Current
affiliation for L.A. Stoddart: The Institute of Cell Signaling, School of Biomed-
ical Sciences, The University of Nottingham, UK
Article, publication date, and citation information can be found at
http://molpharm.aspetjournals.org.
doi:10.1124/mol.110.070789.
□S The online version of this article (available at http://molpharm.
aspetjournals.org) contains supplemental material.
ABBREVIATIONS: GPCR, G protein-coupled receptor; FFA, free fatty acid; SCFA, short-chain fatty acid; 4-CMTB, 4-chloro--(1-methylethyl)-
N-2-thiazolylbenzeneacetamide; ECL2, second extracellular loop; GTPS, guanosine 5-O-(3-thio)triphosphate; eYFP, enhanced yellow fluores-
cent protein; h, human ; ANOVA, analysis of variance; ERK, extracellular signal-regulated kinase; SAR, structure-activity relationship; HDON,
hydrogen bond donor; HACC, hydrogen bond acceptor.
0026-895X/11/8001-163–173$25.00
MOLECULAR PHARMACOLOGY Vol. 80, No. 1
Copyright © 2011 The American Society for Pharmacology and Experimental Therapeutics 70789/3697802
Mol Pharmacol 80:163–173, 2011 Printed in U.S.A.
163
http://molpharm.aspetjournals.org/content/suppl/2011/04/15/mol.110.070789.DC1.html
Supplemental material to this article can be found at: 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
 at A
SPET Journals on January 15, 2017
m
olpharm
.aspetjournals.org
D
ow
nloaded from
 
In cases where selectivity has been achieved through allo-
steric binding sites [e.g., for the muscarinic acetylcholine
receptors (Christopoulos and Kenakin, 2002; Eglen, 2005;
Antony et al., 2009; Conn et al., 2009)], efforts have been
aided by the vast array of molecular and pharmacological
tools available to researchers. This is not the case, however,
for many recently deorphanized GPCRs that are paired with
endogenous ligands possessing only low or moderate potency
for their cognate receptor. Because of their poor potency,
radiolabeling these ligands to examine receptor binding has
not been possible, and maxima of concentration-response
curves are often not clearly defined within the concentration
range practical to employ. Thus, identification of selective
synthetic ligands at these receptors is imperative before
characterization of receptor activation is possible.
Of a number of recently deorphanized GPCRs, a family of
receptors attracting interest is the free fatty acid receptors
(nomenclature as in Alexander et al., 2008), FFA1, FFA2,
and FFA3 (Stoddart et al., 2008b; Milligan et al., 2009),
historically named GPR40, GPR43, and GPR41, respectively
(Brown et al., 2003; Kotarsky et al., 2003; Le Poul et al., 2003;
Nilsson et al., 2003). In particular, FFA2 and FFA3 are both
activated by short-chain fatty acids (SCFAs) of chain lengths
C1 to C5, and we have recently demonstrated a high degree
of similarity in the orthosteric binding pockets of these
closely related receptors (Stoddart et al., 2008a). Although
little is known about the physiological and pathological roles
of these receptors, FFA2 knock-out mice have implicated the
receptor in the regulation of inflammation in models of coli-
tis, arthritis and asthma (Maslowski et al., 2009; Sina et al.,
2009). Furthermore, colonic effects of SCFAs generated via
fermentation processes may play a role in maintaining en-
ergy homeostasis, particularly via FFA2 (Sleeth et al., 2010).
Lee et al., (2008) have reported the phenylacetamide (S)-4-
chloro--(1-methylethyl)-N-2-thiazolylbenzeneacetamide (S-4-
CMTB) as the first selective ligand for FFA2. S-4-CMTB was
shown to be an “ago-allosteric” modulator in that it was both a
direct agonist at FFA2 and also a positive allosteric modulator
of the actions of SCFAs at the receptor (Lee et al., 2008). Given
the potential utility of a selective ligand at FFA2, herein we
have examined the molecular determinants for allosterism and
agonism of this and related compounds at FFA2.We report that
allosteric communication between 4-CMTB and the SCFA pro-
pionate was dependent upon the nature of the second extracel-
lular loop (ECL2), whereby replacement of this region of FFA2
with the equivalent region of FFA3 entirely eliminated alloste-
ric communication at the receptor without limiting direct ago-
nism by either ligand, and even mutation of the single amino
acid Leu173 was sufficient to disrupt allosterism. Thus, ECL2 of
FFA2 acts as a molecular switch to transmit conformational
changes between orthosteric and allosteric binding sites of the
FFA2 SCFA receptor.
Materials and Methods
Materials. Tissue culture reagents were from Invitrogen (Pais-
ley, Strathclyde, UK). Experimental reagents were from Sigma-
Aldrich (Poole, Dorset, UK). Ligands HWD001–HWD009,
HWD011–HWD013, (S)-4-CMTB and (R)-4-CMTB were prepared
in our laboratories as described in Supplemental File 1. Commer-
cially obtained ligands were from Enamine (Kiev, Ukraine)
[HWD014–HWD018, (S)-HWD020, (R)-HWD020] and Pharmeks
(Moscow, Russia) (HWD019). Absence of major secondary prod-
ucts and purity (83–99%) of purchased ligands was confirmed by
high-performance liquid chromatography-photodiode array, high-
performance liquid chromatography-mass spectroscopy (electros-
pray ionization) and 1H-NMR spectroscopy by Laia Miret Casals
and Fernando Albericio (Universitat de Barcelona, Barcelona,
Spain). The radiochemical [35S]GTPS was from PerkinElmer Life
and Analytical Sciences (Beaconsfield, Buckinghamshire, UK).
Site-Directed Mutagenesis and Generation of ECL2 Swap.
Human (h)FFA2 or FFA3 was fused via the C terminus to enhanced
yellow fluorescent protein (eYFP) and subcloned into pcDNA5/
FRT/TO plasmid (Invitrogen), as described previously (Stoddart et
al., 2008a). Primers for polymerase chain reaction of FFA2 (FFA3
ECL2)-eYFP chimeric receptor were designed around the conserved
regions within transmembrane domains 4 and 5 (see Fig. 8). Recep-
tor cDNA was amplified using primers annealing at the N-terminal
and conserved region for one receptor and the conserved region and
C-terminal for the other. These fragments were then combined in a
single polymerase chain reaction where they were allowed to anneal
at the conserved region and act as “primer-templates” to synthesize
the complete chimera. This was then amplified using the N-terminal
primer from the first receptor and the C-terminal primer from the
second. Restriction sites built into the primers were used to subclone
the chimera into pcDNA5/FRT/TO with eYFP as described above.
Cell Culture and Generation of Stable Flp-In T-REx 293
Cells. Cells were maintained in Dulbecco’s modified Eagle’s medium
without sodium pyruvate (Invitrogen) supplemented with 10% (v/v)
dialyzed fetal bovine serum, 1% penicillin/streptomycin mixture, and
10 g/ml blasticidin at 37°C in a humidified atmosphere of air/CO2
(19:1). Inducible Flp-In T-REx 293 cells were generated for each of
hFFA2-eYFP (Stoddart et al., 2008a), and the various receptor mu-
tants and hFFA3-eYFP, as described previously (Stoddart et al.,
2008a; Smith et al., 2009). Antibiotic-resistant clones were screened
for receptor expression by fluorescence imaging and eYFP measure-
ment in membranes using a PHERAStar FS (BMG Labtech, UK).
Cells were treated with 0.5 g/ml doxycycline 24 h before harvesting
or imaging to induce receptor expression.
[35S]GTPS Incorporation Assays. Membranes were prepared
from induced stable cell lines as described elsewhere (Stoddart et al.,
2007). [35S]GTPS binding experiments were performed in duplicate
according to the method of Liu et al. (2009). In brief, 5 g of cell
membranes were added to assay buffer (50 mM Tris-HCl, pH 7.4, 10
mM MgCl2, 100 mM NaCl, 1 mM EDTA, 1 M GDP, and 0.5% fatty
acid-free bovine serum albumin) containing the indicated concentra-
tions of ligands and preincubated for 15 min at 25°C. To initiate the
assay, 50 nCi of [35S]GTPS was added to each tube, and the reaction
was terminated by rapid filtration through GF/C glass filters using a
24-well Brandel cell harvester (Alpha Biotech, Glasgow, UK) after
1-h incubation. Unbound radioligand was washed from filters by
three washes with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, and
10 mM MgCl2), and [
35S]GTPS binding was determined by liquid
scintillation spectrometry. Mutant FFA2 data were normalized to
eYFP fluorescence to account for differences in receptor expression.
Data Analysis. All data were quantified, grouped, and analyzed
using Prism 5.02 (GraphPad Software, San Diego, CA) and are
expressed as mean  S.E.M. Data were fit to both three-parameter
(fixed Hill slope) and four-parameter nonlinear regression isotherms,
and in all cases, the three-parameter curve was statistically appro-
priate. Experimental data from [35S]GTPS binding studies investi-
gating the interaction of 4-CMTB with propionate in wild-type and
mutant FFA2 receptors were analyzed according to the operational
model of allosteric modulation according to Keov et al., (2011) using
the equation
E 
Em(A[A](KB  [B])  B[B]KA)n
([A]KB  KAKB  [B]KA  [A][B])n  (A[A](KB  [B])  B[B]KA)n
in which E indicates the effect and A and B denote the orthosteric
and allosteric ligands, respectively.KA, andKB are the corresponding
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equilibrium dissociation constants of ligand binding to otherwise
unliganded receptors. The cooperativity factor  denotes the alloste-
ric modulation of binding affinity, whereas the empirical parameter
 quantifies the allosteric modulation of orthosteric ligand efficacy;
its values may range between zero and infinity, and it describes the
extent to which the allosteric agent changes the efficacy of the
orthosteric agonist on the ARB (agonist/receptor/modulator) ternary
complex. The ability of the orthosteric and allosteric ligands to favor
receptor activation is described by the parameters A and B, respec-
tively; furthermore, they incorporate the intrinsic efficacy of each
ligand, the total density of receptors, and the efficiency of stimulus-
response coupling. Em denotes the maximal possible system re-
sponse, and n indicates the slope factor of the transducer function by
which occupancy is linked to response. Limitations of the operational
model of allosteric modulation are related to the correlation between
parameters and the dependence of some of these parameters on
system properties (Keov et al., 2011). Therefore, in the current study,
its main use was the determination of semiquantitative estimates of
modulator affinity and overall cooperativity ().
Global nonlinear curve fitting of E as the dependent variable with
A and B as the independent variables yielded estimates for KA, KB,
, , A, and B, except for the data shown in Figs. 7B and 8D, in
which KA and KB were constrained to numerical estimates that had
been obtained from the corresponding global fits of the data sets
illustrated in Figs. 7C and 8E, respectively, because they were am-
biguously resolved if left unconstrained. The results of global non-
linear curve fitting were compared between reciprocally performed
sets of curves by subjecting the numerical values of selected param-
eters to a t test; p  0.05 was considered as the level of significance.
All other statistical analyses were performed as detailed in the text.
Results
4-CMTB Is a Selective Ago-Allosteric Modulator at
FFA2. The phenylacetamide S-4-CMTB has previously been
described as an ago-allosteric ligand at FFA2, acting as both
a direct agonist and a positive allosteric modulator of the
action of SCFAs that are the endogenous activators of this
receptor (Lee et al., 2008). To confirm these findings, we em-
ployed a filtration-based [35S]GTPS binding assay to examine
the ability of racemic 4-CMTB to activate members of the per-
tussis toxin-sensitive Gi/o family of G proteins, because we and
others have demonstrated previously that FFA2 is both a Gi/o
andGq-coupledGPCR (Kimura et al., 2001; Brown et al., 2003;
Le Poul et al., 2003; Stoddart et al., 2008a). In membranes from
Flp-In T-REx 293 cells induced to express wild-type hFFA2
linked to eYFP (hFFA2-eYFP)(Stoddart et al., 2008a), 4-CMTB
was a relatively potent agonist (pEC50  6.38  0.12, mean 
S.E.M.) that producedmaximal responses similar to those of the
endogenous, orthosteric FFA2 agonist propionate (pEC50 
4.12 0.22) for stimulating [35S]GTPS binding and, therefore,
G protein activation (Fig. 1A). 4-CMTB seemed to be specific
Fig. 1. 4-CMTB is a selective ago-allosteric modulator at FFA2. Flp-In TREx 293 cells stably expressing inducible hFFA2-eYFP (A, C, and D) or
hFFA3-eYFP (B) were induced with 0.5 g/ml doxycycline for 24 h before harvesting and membrane preparation for subsequent [35S]GTPS
incorporation assays. A, both 4-CMTB and propionate are full agonists in this assay. Inset, representative example of absolute values [disintegrations
per minute (DPM)] for basal () and propionate (C3; 10 mM) and 4-CMTB (10 M) from a single hFFA2-eYFP membrane preparation. B, 4-CMTB
is not an agonist, antagonist, or allosteric modulator of propionate at the closely related hFFA3-eYFP receptor. Inset, representative experiment for
hFFA3-eYFP, as per A inset. C, 4-CMTB and propionate interact allosterically, as increasing fixed concentrations of 4-CMTB result in enhanced
potency of propionate. The diagonal arrow indicates the shift in potency. , p  0.05 according to one-way ANOVA with Dunnett’s post hoc analysis.
D, the allosteric relationship is reciprocal. Again, the diagonal arrow indicates the shift in potency. , p  0.05 according to one-way ANOVA with
Dunnett’s post hoc test. Data are mean  S.E.M (n  3).
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for hFFA2, because it failed to stimulate [35S]GTPS bind-
ing via the closely related Gi/o-coupled hFFA3 receptor
(Fig. 1B).
A hallmark of allosterism is the ability of a modulator to
alter the potency and/or efficacy of an orthosteric ligand, and
such effects should occur in a reciprocal fashion (Christopou-
los and Kenakin, 2002; Smith et al., 2011). 4-CMTB was also
a positive allosteric modulator of the effects of propionate at
hFFA2 (Fig. 1C). The potency of propionate was increased in
the presence of increasing concentrations of 4-CMTB (pEC50
range, 3.90  0.09 in the absence of 4-CMTB to 5.16  0.33
in the presence of 105 M 4-CMTB, p  0.05 according to
one-way ANOVA). It is noteworthy that this effect was recip-
rocal, because the potency of 4-CMTB was also increased in
the presence of increasing concentrations of propionate (Fig.
1D; pEC50 range: 6.31  0.08 in the absence of propionate to
7.20  0.31 in the presence of 103 M propionate, p  0.05
according to one-way ANOVA). Global analyses of the data
were performed using the operational model of allosteric
modulation as described previously (Keov et al., 2011), which
led to the estimation of strongly positive overall cooperativity
() of 4-CMTB and propionate at wild-type FFA2. Such
analyses also yielded estimates of the affinity of propionate
(pKA  3.20  0.29) and 4-CMTB (pKB  5.26  0.43).
Furthermore, the  values obtained for curves in Fig. 1, C
and D were not significantly different from each other, sup-
porting reciprocity of effect (average   194). 4-CMTB was
also selective for hFFA2 with respect to allosterism, in that it
was not able to positively or negatively allosterically modu-
late the effect of propionate at hFFA3-eYFP (Fig. 1B).
4-CMTB Is a Partial Agonist at ERK1/2 and Is Spe-
cific for FFA2.We also examined the actions of 4-CMTB at
the mitogen-activated protein kinase ERK1/2 pathway and
found it to be a reasonably potent (pEC50  6.59  0.23) but
partial (p  0.05) agonist with respect to propionate (pEC50 
4.03  0.21) (Fig. 2A). As for the [35S]GTPS assay, 4-CMTB
was neither an agonist nor an antagonist at hFFA3-eYFP or
hFFA1-eYFP (Fig. 2, B and C) when ERK1/2 phosphorylation
was recorded as the signal, further supporting 4-CMTB
selectivity.
4-CMTB Does Not Bind within the Orthosteric Bind-
ing Site of hFFA2. Allosteric modulators, by definition,
bind at a site(s) distinct from orthosteric ligands. We have
previously used site-directed mutagenesis, in concert with
SCFA-mediated phosphorylation of ERK1/2 and the eleva-
tion of [Ca2]i, to define critical orthosteric residues of
hFFA2 (Stoddart et al., 2008a). Herein, membranes produced
from Flp-In T-REx 293 cells induced to express R(5.39)A
(residue 180) or R(7.35)A (residue 255) hFFA2-eYFP [num-
bered according to the system of Ballesteros and Weinstein
(1995)] did not promote [35S]GTPS binding in response to
propionate, presumably because the arginines act to coordi-
nate the carboxylate head group of the SCFA, as they do for
FFA1 and FFA3 (Sum et al., 2007; Smith et al., 2009). For
H(4.56)A (residue 140) there was a trend toward reduced
potency, whereas for H(6.55)A (residue 242) hFFA2-eYFP,
propionate potency was reduced (p  0.01 according to a
one-way ANOVA), although function was not eliminated
(Fig. 3A). In contrast, 4-CMTB stimulated [35S]GTPS bind-
ing, in each case with unaltered potency (p  0.05) and with
limited effects on maximal signal (Fig. 3B), and this was also
the case in membranes containing a double R(5.39)A 
R(7.35)A mutation of hFFA2-eYFP (Fig. 3B), indicating that
these key residues of the orthosteric binding pocket of hFFA2
are not involved directly in 4-CMTB binding and receptor
activation. It is noteworthy that radioligands are still
not available for FFA2; thus, intensity of eYFP was mea-
sured as a surrogate for hFFA2 expression, even though this
approach cannot clearly define cell-surface expression (Table 1).
Although we found that expression was lower than wild type
for each of these five mutants, in no case was the difference
greater than 2-fold.
Fig. 2. 4-CMTB is a partial agonist at ERK1/2 and is selective for FFA2
compared with FFA3 and FFA1. A, Flp-In TREx 293 cells stably express-
ing FFA2-eYFP were stimulated for 10 min with varying concentrations
of propionate (C3) or 4-CMTB and processed for ERK1/2 activation using
the AlphaScreen SureFire ERK1/2 assay (PerkinElmer Life and Analyt-
ical Sciences). , p  0.05 for 4-CMTB Emax being less than that for
propionate according to Student’s t test. Data are mean  S.E.M (n  3).
B, equivalent experiments were performed using hFFA3-eYFP cells (n 
3), where only propionate was an agonist in the ERK1/2 pathway.
C, Western blots of hFFA3-eYFP cell lysates treated as for B. Fetal bovine
serum [10% (v/v)] was included as a positive control for ERK1/2 activa-
tion. D, Western blot as described for C, except that cells expressing
FFA1-eYFP were stimulated with 100 M lauric acid. PT, pretreatment.
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4-CMTB Structure-Activity Relationships at FFA2.
To elucidate the structural features of 4-CMTB that contrib-
ute to its binding and activity, we undertook a concise struc-
ture-activity relationship (SAR) survey with a series of
4-CMTB analogs (Fig. 4) using hFFA2-eYFP in the
[35S]GTPS assay. The [35S]GTPS assay was deemed ideal
for our SAR studies because it is the most receptor-
proximal assay available, and we found propionate and
4-CMTB to have equal efficacy in this assay (unlike for
ERK1/2 in Fig. 2A and [Ca2]I; data not shown). For our
targeted SAR, we focused primarily on isopropyl replace-
ment variants (compounds HWD001–HWD008, HWD018,
and HWD020) and amide N-substituent variants (HWD009,
HWD011–HWD017).
Isopropyl replacement variants displayed a chain length
dependence for stimulating [35S]GTPS binding at a maxi-
mally effective concentration (105 M) (Fig. 5A). The greatest
maximal effect with n-alkyl chains from C1 to C5 was seen
with ethyl (HWD003), a chain length equivalent to the iso-
propyl group of the parent ligand, although all of the com-
pounds exhibited enhanced activity over the -unsubstituted
analog (HWD001). Disubstitution at the -carbon, whether
by methyl or bulkier butyl groups, compromised activity
(HWD007 and HWD008). Although none of the ligands dis-
played enhanced (or even equivalent) potency compared with
the parent 4-CMTB, potency values were generally within a
log unit of 4-CMTB (Table 2). A compound (HWD018) with a
phenyl replacement for the 4-CMTB isopropyl group was
commercially available but lacked the parent ligand’s chlo-
rine atom. We therefore extended the SAR survey to include
this compound and 3-methyl-2-phenyl-N-(thiazol-2-yl)bu-
tanamide (HWD019), also commercially available, to allow
incremental analysis of the effects of removing the 4-CMTB
chlorine and replacing the isopropyl group by phenyl.
HWD018 was active as an agonist at FFA2, albeit with sig-
nificantly reduced potency compared with 4-CMTB (Table 2).
This reduced potency and efficacy is directly attributable to
the phenyl replacement of the isopropyl group rather than
removal of the chlorine, however, because HWD019 largely
retained the efficacy and potency of 4-CMTB (Table 2). As
4-CMTB is an ago-allosteric modulator of hFFA2 (Fig. 1), we
also examined whether the relatively conservative replace-
ment of the isopropyl group by butyl in HWD004 affected
allosterism. As shown in Fig. 5B, addition of a fixed concen-
tration of HWD004 also produced a significant increase in
potency of propionate, consistent with positive allosteric
modulation. Thus, a single moderately bulky alkyl group at
the -carbon favors agonist activity, with optimal activity
conferred on 4-CMTB itself by the -branched isopropyl
group. An ethyl replacement had little impact on efficacy but
caused a 6-fold reduction in potency, whereas longer/larger
groups and smaller groups compromise both potency and
efficacy. The allosteric action of the ligands seems to be
tolerant of isopropyl replacement, at least in the case of a
butyl group.
The effect of amide N-substituent alteration was more
variable. Introduction of a methyl group at the 5-position of
the thiazole (HWD017) or replacement of the thiazole by
4,5-dihydrothiazole (HWD014) were well tolerated (Table 2),
the latter substitution indicating that a (hetero)aromatic N-
substituent is not absolutely required for activity. In con-
trast, more radical changes to the amide N-substituent pro-
foundly influenced activity, and replacement of the thiazolyl
ring by cyclooctyl (HWD015) or acetylaminoethyl (HWD016)
completely abolished agonism (Fig. 5C). Because the N-thia-
zolyl amide might provide key hydrogen bonding features in
binding to FFA2, we examined the impact of N-methylation
on 4-CMTB and replacement of the thiazole by pyridyl
groups. Significantly, N-methylation (HWD013) ablated ac-
tivity, potentially consistent with the amide NH binding to
FFA2 as a hydrogen bond donor (HDON). The analog
(HWD011) with an N-(2-pyridyl)- group, a thiazole replace-
Fig. 3. 4-CMTB does not require a functional orthosteric ligand binding
site for signaling. Flp-In TREx 293 cells stably expressing inducible
wild-type or orthosteric binding site mutants of hFFA2-eYFP (Stoddart et
al., 2008a) were induced with 0.5 g/ml doxycycline for 24 h before
harvesting and membrane preparation for subsequent [35S]GTPS incor-
poration assays. A, mutation of either R(5.39)A, R(7.35)A, or both resi-
dues (RARA) completely abolishes propionate activity, whereas propi-
onate potency is markedly impaired at the H(6.55)A mutation. , p 
0.01 according to a one-way ANOVA with Dunnett’s post hoc test.
B, 4-CMTB potency is unaltered at any of the orthosteric binding site
mutants of hFFA2-eYFP. Efficacy was only significantly impaired for
R(7.35)A. , p  0.05 according to one-way ANOVA with Dunnett’s post
hoc analysis. Data are mean  S.E.M with experiment repeats indicated
in parentheses.
TABLE 1
FFA2 mutant receptor expression per 5 g of protein as determined by
eYFP fluorescence
Values are presented as mean  S.E.M.
FFA2 Receptor eYFP n
RLU
HEK293 no receptor 556  25.9
Wild type 4193  405 4
H140A (4.56) 2110  320 4
L173A (ECL2) 2041  431 3
R180A (5.39) 1798  187 6
H242A (6.55) 2655  101 5
R255A (7.35) 3024  201 5
R180A/R255A (5.39/7.35) 2072  101 3
FFA2 (ECL2 FFA3) 1886  112 3
RLU, relative light unit; HEK, human embryonic kidney.
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ment of slightly increased size but preserving the endocyclic
nitrogen as a potential hydrogen bond acceptor (HACC) site
adjacent to the amide NH, possessed activity similar to that
of 4-CMTB itself. In contrast, the isosteric N-(3-pyridyl)- and
N-(4-pyridyl)-substituted ligands (HWD009 and HWD012),
in which the endocyclic nitrogen is moved progressively
around the ring, showed substantially reduced activity
(HWD009) or no activity (HWD012) (Table 2). These results
are consistent with a hydrogen bond acceptor role for the
endocyclic nitrogen of 4-CMTB that is maintained in
HWD011. In principle, this type of HACC/HDON combina-
tion might form a complementary binding motif for amide
functionality in the protein (i.e., Asn/Gln side chains or the
protein backbone, as seen in cocrystal structures of other
proteins with N-(thiazol-2-yl)amide-containing ligands (Jad-
hav et al., 1997; Kamata et al., 2004)).
We next examined HWD015, HWD016, and the lower effi-
cacy isopropyl replacement analogs HWD001 and HWD008
for evidence of allosteric activity in the presence of propi-
onate (Fig. 5D). Consistent with the previous findings, single
concentrations (10 M) of HWD015 and HWD016 displayed
no direct agonism, whereas HWD001 and HWD008 caused
small increases in G protein activation. However, none of
these compounds altered propionate potency at hFFA2-
eYFP, indicating either an absence of allosterism or, as is
most likely to be the case for the low efficacy compounds
HWD001 and HWD008, an effect on propionate binding and
function that is beyond the sensitivity of this assay. Finally,
to determine whether HWD015 and HWD016 were in fact
binding to hFFA2 and acting therefore as simple antagonists
of 4-CMTB, each of the ligands was coincubated with increas-
ing concentrations of 4-CMTB. As shown in Fig. 5E, neither
amide N-substituent variant was able to modulate 4-CMTB
agonism, indicating that these ligands are not able to bind to
the receptor with significant affinity. As anticipated, coun-
terscreening of the SAR ligands at hFFA3-eYFP revealed all
but one compound to be inactive; only HWD017 was able to
partially stimulate [35S]GTPS at the very highest concen-
tration used (3  105 M) (not shown).
The S-Isomer Is Required for Maximal Biological
Activity of 4-CMTB. In the study that identified 4-CMTB as
an agonist at FFA2, the authors described only the use of the
S-stereoisomer of 4-CMTB (Lee et al., 2008). To further char-
acterize 4-CMTB structure and function, and in light of the
reasonable tolerance of racemic mixes of isopropyl group
substitutions described in Fig. 5, we prepared both R- and
S-4-CMTB and examined their activity alone and in combi-
nation at hFFA2-eYFP. S-4-CMTB was slightly more potent
and efficacious at hFFA2 than the racemate (Fig. 6A) and
produced maximal responses similar to those of the or-
thosteric agonist propionate. It is noteworthy thatR-4-CMTB
was also able to stimulate G protein activity with greater
potency than propionate but significantly lower efficacy than
either S- and racemic 4-CMTB or propionate. No signal was
observed for racemic, S-, or R-4-CMTB at FFA3 (Fig. 6B),
indicating that the stereochemistry of 4-CMTB was not re-
sponsible for differences in selectivity at hFFA2 versus
hFFA3. Attempts to perform Schild analysis to determine the
apparent affinity of 4-CMTB for hFFA2 using the stereoiso-
mers were unsuccessful, because we were unable to add
sufficient R-4-CMTB to compete with S-4-CMTB (Fig. 6C).
Finally, given that an ethyl replacement for the bulkier iso-
Fig. 4. Analogs used for 4-CMTB SAR survey.
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propyl group in racemic 4-CMTB retained agonist efficacy in
HWD003, we examined separate enantiomers for an -ethyl-
substituted compound. Conveniently, both antipodes of the
unchlorinated -ethyl analog HWD020 were commercially
available. Only S-HWD020 promoted [35S]GTPS binding
within the concentration range that could be employed
(Fig. 6D) and this was not inhibited by increasing concen-
trations of R-HWD020 (Fig. 6D, inset) indicating that only
S-HWD020 is able to bind to the receptor within concen-
tration ranges practical to test. Thus, although enantio-
pure compounds are not critical for function, 4-CMTB-
related ligands with an S-configured stereogenic center at
Fig. 5. Function of selected 4-CMTB SAR ligands at hFFA2-eYFP. A, 4-CMTB isopropyl replacement variants (replacement area on 4-CMTB indicated
on the structure by a circle) in the [35S]GTPS incorporation assay demonstrate chain length and bulk dependence for maximal efficacy. Significant
differences from 4-CMTB maximum are indicated. , p  0.05, , p  0.01; n.s., not significant, according to one-way ANOVA with Dunnett’s post
hoc analysis (n  4). B, HWD004 is also a positive allosteric modulator at 10 M in the presence of increasing propionate concentrations. Arrow
indicates shift in potency. , p  0.05 according to Student’s t test. C, not all 4-CMTB analogs displayed agonist activity at hFFA2-eYFP. D, inactive
(HWD015 and HWD016) or weakly efficacious (HWD001, HWD008) ligands were tested for allosterism (10 M fixed concentration of HWD ligands)
but failed to alter the potency of propionate. n.s., no significant difference in potencies according to one-way ANOVA. E, neither HWD015 nor HWD016
could compete at 10 M with 4-CMTB at hFFA2-eYFP. Data represent mean  S.E.M. of three independent experiments.
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the -position are the preferred agonists for G protein
activation.
Allosterism Is Impaired at Leu173Ala hFFA2-eYFP.
One of the key residues suggested by Lee et al. (2008) to
contribute to recognition of 4-CMTB by FFA2 was Leu173,
located in ECL2 of hFFA2. Their preferred homology model
predicted an H-bond interaction between Arg255(7.35) and
the carbonyl backbone of Leu173. Given this link between the
possible site of binding of the orthosteric and allosteric li-
gands and the requirement that there must be communica-
tion between such sites to produce reciprocal modulation of
ligand function, we explored allosterism at a Leu173Ala mu-
tant of hFFA2-eYFP. Both propionate and 4-CMTB were, on
their own, effective agonists at Leu173Ala-hFFA2-eYFP with
potencies similar to that of wild-type hFFA2-eYFP (Fig. 7A).
Global analysis of allosteric interactions (Keov et al., 2011) in
Fig. 7, B and C, as per Fig. 1, revealed that overall alloster-
ism was both reciprocal and significantly reduced for this
mutant (Table 3) compared with wild-type FFA2 (average
  21, p  0.01 according to one-way ANOVA with New-
man-Keuls multiple comparison test). Thus, the overall
structure of FFA2 ECL2 was considered for involvement in
the transmission of allosterism between propionate and
4-CMTB.
Allosterism, but Not Agonism, Is Abolished by an
ECL2 Swap Between hFFA2 and hFFA3. Given the ap-
preciated difficulties in trying to predict specific ECL confor-
mations (Peeters et al., 2011), we decided to further explore
the role of ECL2 in 4-CMTB allosterism and agonism by
taking advantage of the observation that 4-CMTB selectively
activates hFFA2 but not the closely related hFFA3 receptor
(as demonstrated in Fig. 1). Thus, we generated a
hFFA2(ECL2 hFFA3)-eYFP chimera in which ECL2 of
hFFA3 replaced the equivalent sequence of hFFA2 (Fig. 8A).
Again, a stable Flp-In T-REx 293 cell line able to induce
expression of this construct was generated and tested ini-
tially for signaling to propionate as a measure of correct
folding of the receptor (Fig. 8B). It is noteworthy that
hFFA2(ECL2 hFFA3)-eYFP retained propionate responsive-
ness. Furthermore, 4-CMTB potency was equivalent to that
of wild-type hFFA2-eYFP, indicating that the binding of
4-CMTB is largely unperturbed by the differences in both
amino acid sequence and potentially broader conformational
dissimilarities between hFFA2 and hFFA3 in this region
(Fig. 8C). However, maximal efficacy was reduced for both
ligands, reflecting either the significantly reduced receptor
Fig. 6. S-4-CMTB is more potent than R-4-
CMTB at hFFA2-eYFP. A, racemic 4-CMTB
and individual stereoisomers were examined
for their ability to promote [35S]GTPS incor-
poration. R-4-CMTB was significantly less po-
tent and efficacious thanboth racemic 4-CMTB
and S-4-CMTB, according to one-way ANOVA
with Dunnett’s post hoc analysis. , p  0.05;
, p 0.01. B, 4-CMTB stereoisomers are not
active at the closely related hFFA3-eYFP.
C, R-4-CMTB and S-4-CMTB are not additive
when coincubated, suggesting binding to the
same site on hFFA2-eYFP. D, only the S-iso-
mer of the structurally related ligandHWD020
is able to activate hFFA2-eYFP. Inset,
R-HWD020 is unable to inhibit signaling in
response to 30 M S-HWD020. Data are
mean  S.E.M (n  3) for all panels.
TABLE 2
Structure-activity relationship of 4-CMTB-based ligands at 	35S
GTPS
assay of G protein activation
Values are presented as mean  S.E.M. Emax is expressed as a percentage of
propionate signal. Inactive is defined as 10% propionate maximum signal at the
highest concentration tested (10 M).
Ligand
FFA2-eYFP
n
pEC50 Emax
%
Propionate 4.39  0.26 100.0  4.0 3
4-CMTB 6.18  0.18 105.2  3.8 3
S-4-CMTB 6.52  0.12 118.9  5.2 3
R-4-CMTB 5.74  0.09 77.7  4.0 3
HWD001 5.24  0.56 69.6  3.0 3
HWD002 5.50  0.30 81.3  3.5 3
HWD003 5.38  0.13 103.4  3.5 3
HWD004 5.64  0.17 90.0  2.6 3
HWD005 5.50  0.19 92.6  3.3 3
HWD006 5.67  0.38 80.1  4.4 3
HWD007 4.99  0.25 88.8  6.0 3
HWD008 5.04  0.48 80.9  9.0 3
HWD009 5.05  0.30 37.1  7.3 3
HWD011 6.58  0.11 128.7  6.4 3
HWD012 Inactive Inactive 3
HWD013 Inactive Inactive 3
HWD014 5.39  0.26 90.0  4.4 3
HWD015 Inactive Inactive 3
HWD016 Inactive Inactive 3
HWD017 6.11  0.20 100.7  3.2 3
HWD018 4.72  0.33 77.5  6.6 3
HWD019 5.84  0.25 96.6  3.4 3
S-HWD020 5.27  0.16 95.2  13.1 3
R-HWD020 Inactive Inactive 3
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expression of this chimera or subtle structural differences
affecting receptor activation. Despite retention of agonism,
however, allosteric communication between propionate and
4-CMTB was now completely abolished (Fig. 8, D and E;
Table 3; average   1.2). Thus, it seems that either the
nonconserved residues in ECL2 or the overall conformation
of this region is required for allosterism between 4-CMTB
and an orthosteric agonist at hFFA2. The importance of
ECL2 in receptor activation has been shown for several
GPCRs (Sum et al., 2009; Bokoch et al., 2010). Because it is
impossible to accurately predict the conformation of ECL2
using comparative modeling, it is difficult, therefore, to pro-
vide a mechanistic basis for the influence of ECL2 on
4-CMTB allosterism.
Discussion
The free fatty acid receptor FFA2 is attracting considerable
interest because of its potential role in the regulation of
inflammation and the importance of gut microflora in gener-
ating SCFAs that activate this receptor. However, selectivity
between FFA2 and the closely related receptor FFA3 remains
problematic (Brown et al., 2003; Le Poul et al., 2003; Stod-
dart et al., 2008a,b). Although selective orthosteric ligands
have not yet been reported for either FFA2 or FFA3, a pair of
recent studies has identified a series of ligands, based on the
phenylacetamide S-4-CMTB, that are thought to circumvent
this issue by binding to an allosteric site on FFA2 (Lee et al.,
2008; Wang et al., 2010). Using the predominantly Gi/o-
specific [35S]GTPS binding assay to examine both wild-type
and mutated versions of hFFA2, we confirmed both the direct
agonism and positive allosteric effects on the function of the
SCFA propionate by 4-CMTB and related ligands. In previ-
ous studies, we had identified key basic residues in FFA2, on
the basis of alignments of FFA2 with both FFA3 and FFA1
and the recognition that corresponding fatty acid amides are
not agonists at these receptors (Stoddart et al., 2008a), that,
after mutation, either eliminated or substantially reduced
the potency of SCFAs at FFA2. This allowed us to define, in
part, the mode of binding of the orthosteric SCFAs at both
FFA2 and FFA3 (Stoddart et al., 2008a). It is noteworthy
that mutation of these key residues, His4.56, Arg5.39,
His6.55, and Arg7.35, did not alter the measured potency of
4-CMTB, confirming that 4-CMTB does not share a common
binding site with the SCFAs.
These studies were combined with a targeted SAR survey
of 4-CMTB analogs to investigate the possible mode of bind-
ing of the phenylacetamides. The SAR survey focused on
variations in the ligand’s -substitution andN-(thiazolyl)am-
ide substructure, the latter because we envisaged that it
might constitute a key hydrogen bonding motif for binding
the receptor. Our SAR data are in close agreement with those
recently disclosed by Wang et al. (2010) during the course of
our work. Together, the results of these two studies are
consistent with a receptor-bound state for the ligand that
exhibits a near coplanar conformation for the N-(thiazolyl)-
amide functionality and in which the amide NH and thiazole
nitrogen present, respectively, HDON and HACC sites for
engagement of the protein. Precisely this conformational or-
ganization and functional role is seen in the cocrystal struc-
tures of two unrelated N-(2-thiazolyl)amide-containing com-
pounds bound to human glucokinase and HIV protease
(Jadhav et al., 1997; Kamata et al., 2004). In both instances,
the N-(thiazolyl)amide engages two adjacent peptide link-
ages in the protein backbone, and a corresponding engage-
ment in FFA2 would therefore implicate interaction of the
Fig. 7. Leu173 in hFFA2-eYFP is required for 4-CMTB allosterism but not
agonism. A Leu173Ala mutation was introduced into the 2nd extracellular
loop of hFFA2-eYFP, and this inducible construct was expressed stably in
Flp-In TREx 293 cells. A, [35S]GTPS incorporation in response to either
propionate (pEC50  3.95  0.15) or 4-CMTB (pEC50  6.14  0.06) is
unaffected by L173A mutation within hFFA2-eYFP. B, coincubation of
L173A hFFA2-eYFP with fixed concentrations of 4-CMTB and varying
amounts of propionate no longer resulted in a significant shift in the
potency of propionate, indicated by the arrow. n.s., not significant accord-
ing to one-way ANOVA. C, the loss of allosterism was reciprocal, with no
significant difference in pEC50 range indicated by the arrow. n.s., not
significant according to one-way ANOVA. Data are mean S.E.M (n 3)
in each panel.
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motif with a loop region rather than the core transmembrane
helices, wherein the backbone hydrogen bonding sites are
sequestered in intrahelix interactions. At the present
stage, however, we cannot discount other engagement modes
for the N-(thiazolyl)amide, such as hydrogen bonding to side-
chain amide functionality in Asn or Gln residues. From the
compounds with -alkyl group variations, it seems that a C2
chain length is optimal, although branching at the  carbon,
as in the isopropyl group of 4-CMTB itself, is preferred for
ligand potency. It is noteworthy that Wang et al. (2010)
reported that only the S-enantiomer of 4-CMTB possessed
biological activity when measuring regulation of cAMP, al-
though they also demonstrated that a requirement for chiral
structures was not absolutely necessary for ligand function
by showing that ligands having the -carbon as part of a
cycloalkyl group can retain a good measure of the activity of
4-CMTB. In our [35S]GTPS binding assay, however, we
found R-4-CMTB to be only 6-fold less potent than the race-
mic material or separate S-enantiomer of 4-CMTB, suggest-
ing that the absolute configuration of the ligand may be less
critical for activity than originally indicated.
A key finding of our study was that apparent allosteric
communication between orthosteric and allosteric sites
within hFFA2 was reduced by a single point mutation within
ECL2 (L173A) and abolished by replacement of ECL2 from
FFA2 with that of FFA3. This finding was confirmed both by
loss of significant shifts in potency with increasing concen-
trations of modulating ligand and by significant reduction of
global cooperativity estimates (Table 3). In both cases, this
occurred without any change in propionate or 4-CMTB po-
tency as direct agonists. Although a truly striking set of
observations, such interactions remain impossible to model
structurally. The available atomic level structures of GPCRs
show ECL2 to adopt very different conformations (Peeters et
al., 2011), and it is simply impractical to estimate this de
novo with any expectation of accuracy. However, these data
clearly demonstrate the importance of this region in commu-
nication between the two binding sites and are consistent
with the appreciated role of ECL2 in receptor activation
(Bane`res et al., 2005; Conner et al., 2007; Scarselli et al.,
2007; Huber et al., 2008; Ahn et al., 2009; Bokoch et al., 2010;
Unal et al., 2010; Peeters et al., 2011). To date, the best
attempt to delineate the molecular mechanisms of alloster-
ism, efficacy, and cooperativity have been at the M4 musca-
rinic acetylcholine receptor, although these required a series
of well-defined and selective probes, including dualsteric li-
Fig. 8. 4-CMTB requires the second extra-
cellular loop of hFFA2 for allosteric modu-
lation of propionate. The 2nd extracellular
loop of hFFA2 (Val144–Glu182) was replaced
with ECL2 from the closely related hFFA3
receptor (Val150–Glu187) to generate an
hFFA2(ECL2 FFA3)-eYFP chimeric pro-
tein and stable Flp-In TREx 293 cells gen-
erated as before. A, extracellular loop 2
alignment between hFFA2 and hFFA3 us-
ing ClustalX (accession numbers: hFFA2,
NP005297; hFFA3, NP005295). B, propi-
onate activates hFFA2(ECL2 FFA3)-eYFP
with equivalent potency to hFFA2-eYFP
WT (pEC50  3.96  0.09 and 4.03  0.14,
respectively; n  4) but with marginally
reduced efficacy (p  0.0501 according to
an unpaired t test). C, 4-CMTB has signifi-
cantly reduced efficacy at hFFA2(ECL2 FFA3)
compared with hFFA2-eYFP WT (p  0.001
according to an unpaired t test). Potency is
equivalent betweenWTand chimeric receptors
according to a t test (pEC50  6.50 0.15 and
6.75 0.11, respectively; n 4). D, allosterism
between 4-CMTB and propionate is lost at the
hFFA2(ECL2 FFA3)-eYFP chimera. The ar-
row indicates potency; n.s. represents no signif-
icant difference in potency values according to
one-way ANOVA (n  3). E, reciprocal loss of
allosterism at hFFA2(ECL2 FFA3)-eYFP ac-
cording to one-way ANOVA and indicated by
the arrow (n  3).
TABLE 3
Parameters obtained from the operational model of allosteric modulation, where A is propionate (fixed concentrations) and B is 4-CMTB (variable
concentrations)
FFA2 WT FFA2 L173A FFA2 (ECL2 FFA3)
Mean S.E.M. Mean S.E.M. Mean S.E.M.
logKA 3.20 0.29 3.13 0.30 3.82 0.27
logKB 5.26 0.43 5.27 0.37 6.43 0.26
log 1.88 0.59 0.82 0.56 0.13 0.42
log 0.31 0.11 0.66 0.21 0.23 0.11
log 2.19 0.71 1.48 0.78 0.36 0.53
 155 30* 2.3**
* P  0.05 according to one-way ANOVA with Newman-Keuls multiple comparisons post hoc analysis.
** P  0.01 according to one-way ANOVA with Newman-Keuls multiple comparisons post hoc analysis.
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gands, and existing knowledge of allosteric and orthosteric
binding sites (Nawaratne et al., 2010). Clearly, much re-
mains to be determined with respect to the mechanism of
allosteric signal propagation at FFA2 and will depend upon
the development of more potent and selective ligands and
greater understanding of ligand binding at both orthosteric
and allosteric sites on the receptor.
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SUPPLEMENTARY METHODS 
 
Compound Synthesis 
 
General details 
Commercially available reagents from Aldrich and Alfa Aesar chemical companies were 
generally used as supplied without further purification. Tetrahydrofuran (THF) was dried by 
distillation from sodium-benzophenone ketyl under argon. ‘Light petroleum’ refers to the 
fraction boiling between 40 °C and 60 °C.  Dichloromethane was dried by distillation from 
calcium hydride. Anhydrous N,N-dimethylformamide (DMF) was purchased from Aldrich and 
used as supplied from Sure/SealTM bottles. Reactions were routinely carried out under an 
inert atmosphere of argon or nitrogen. Analytical thin layer chromatography was carried out 
using aluminium backed plates coated with Merck Kieselgel 60 GF254 (Art. 05554). 
Developed plates were visualized under ultra-violet light (254 nm) and/or alkaline potassium 
permanganate dip.  Flash chromatography was performed using DAVISIL® silica (60 Å; 35-
70 µM) from Fisher (cat. S/0693/60). Fully characterized compounds were 
chromatographically homogeneous. 
Melting points were determined using a Stuart Scientific SMP10 apparatus and are 
uncorrected. Mass spectra were obtained on a Kratos Concept IS EI (electron impact) 
spectrometer. 1H NMR spectra were recorded at 200 and 400 MHz on Bruker AC200 and 
DPX400 spectrometers; 13C NMR spectra were recorded at 50 and 101 MHz on the same 
instruments. Chemical shifts are recorded in parts per million ( in ppm) and are referenced 
against solvent signals (C 77.16 for chloroform and C 39.52 for methyl sulfoxide) for 13C 
spectra and solvent residual resonances (H 7.26 for chloroform and H 2.50 methyl 
sulfoxide) for 1H spectra.1 Chemical shift values are accurate to ±0.01 ppm and ±0.1 ppm 
respectively. J values are given in Hz. Multiplicity designations used are: s, d, t, q, sept and 
m for singlet, doublet, triplet, quartet, septet and multiplet respectively. In 13C NMR spectra, 
signals corresponding to CH, CH2, or CH3 groups are assigned from DEPT. Elemental 
analyses were carried out by the analytical service of the Chemistry Department at Heriot-
Watt University using an Exeter CE-440 Elemental Analyser. Enantiomeric excess was  
                                                 
1 H. E. Gottlieb, V. Kotlyar and A. Nudelman, J. Org. Chem., 1997, 62, 7512-7515. 
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determined by chiral HPLC analysis using a Phenonenex Lux 3 Cellulose-2 1000Å 150 x 
4.6 mm column with 20% 2-propanol in hexane as the isocratic eluent and a flow of 0.2 
ml/min with a column temperature of 30 oC. 
 
(rac)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide (4-CMTB) 
(rac)-2-(4-chlorophenyl)-3-methylbutanoic acid 
A solution of n-BuLi (2.5 M / hexane; 220 mL, 550 mmol) was added dropwise to a stirred 
solution of (4-chlorophenyl)acetic acid (22.4 g, 131 mmol) in THF (350 mL) at –78 °C; the 
mixture was then warmed to 0 °C for 1 h. The reaction mixture was cooled to –78 °C and 
isopropyl iodide (42.0 mL, 420 mmol) was added. The mixture was allowed to come to 
ambient temperature over 18 h, resulting in partial precipitation of the lithium salt of 2-(4-
chlorophenyl)-3-methylbutanoic acid. The latter was collected by filtration and the filtrate 
concentrated in vacuo to remove THF. The carboxylate salt was recombined with resulting 
residue and partitioned between dilute hydrochloric acid and EtOAc. The organic layer was 
washed successively with 10% sodium metabisufite solution, water and saturated brine; 
dried (Na2SO4) and evaporated. The crude product thus obtained was purified by flash 
column chromatography (100% CH2Cl2) to afford the title compound (17.9 g; 64%) as white 
powder:  mp 93–96 °C (CH2Cl2);  H (200 MHz; CDCl3) 10.88 (1 H, OH, broad s), 7.33 – 7.23 
(4 H, m, chlorophenyl), 3.12 (1 H, d, J 10.6, -CH), 2.29 (1 H, double septet, J 10.6 and 6.5, 
isopropyl CH), 1.07 (3 H, d, J 6.5, Me), 0.70 (3 H, d, J 6.6, Me); C (50 MHz; CDCl3) 180.0 
(C=O), 136.3 (aromatic C), 133.6 (aromatic C), 130.1 (aromatic CH×2), 128.9 (aromatic 
CH×2), 59.5 (-CH), 31.9 (isopropyl CH), 21.6 (Me), 20.2 (Me);  m/z (EI) 212 (M+ 35Cl, 75%);  
(found: C, 62.29; H, 6.28. C11H13ClO2 requires C, 62.12; H, 6.16%). 
 
(rac)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide (4-CMTB) 
A stirred mixture of (rac)-2-(4-chlorophenyl)-3-methylbutanoic acid (1.60 g; 7.52 mmol) and 
thionyl chloride (0.58 mL, 8.0 mmol) in anhydrous CH2Cl2 (10 mL) was heated at reflux 
under a nitrogen atmosphere. After 3 h the mixture was cooled and evaporated. The crude 
acid chloride was reconstituted with anhydrous CH2Cl2 (10 mL) and the resulting solution 
added dropwise under a nitrogen atmosphere into a stirred mixture of 2-aminothiazole (2.07 
g, 20.7 mmol) and triethylamine (2.40 mL, 17.2 mmol) in anhydrous CH2Cl2 (30 mL). The 
resulting mixture was then heated under reflux. After 16 h the mixture was cooled to ambient 
temperature and washed successively with dilute hydrochloric acid, saturated sodium 
bicarbonate solution and saturated brine. The organic layer was dried (Na2SO4) and 
evaporated to afford a residue that was subjected to flash column chromatography (1:4 
EtOAc/light petroleum), furnishing the title compound (1.56 g g; 70%) as white powder:  mp 
195–197 °C;  H (200 MHz; CDCl3) 11.98 (1 H, broad s, NH), 7.56 (1 H, d, J 3.7, thiazole), 
7.27 (4 H, app. s, chlorophenyl), 7.09 (1 H, d, J 3.7, thiazole), 3.21 (1 H, d, J 10.4, -CH), 
2.50 (1 H, double septet, J 10.4 and 6.5, isopropyl CH), 1.06 (3 H, d, J 6.5, Me), 0.79 (3 H, d, 
J 6.6, Me);  C (50 MHz; CDCl3) 171.7 (C=O), 160.0 (thiazole C-2), 136.5 (aromatic C), 136.4  
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(thiazole CH-4), 133.6 (aromatic C), 129.8 (aromatic CH×2), 129.0 (aromatic CH×2), 114.3 
(thiazole CH-5), 60.8 (-CH), 32.3 (isopropyl CH), 21.6 (Me), 20.6 (Me);  m/z (EI) 294 (M+ 
35Cl, 35%), 194 (57%), 167 (62%), 125 (100%);  (found: C, 56.95; H, 5.12; N, 9.69. 
C14H15ClN2OS requires 57.04; H, 5.13; N, 9.50%). 
(R)-(-)-2-(4-chlorophenyl)-3-methylbutanoic acid ((-)-CPA) and (S)-(+)-2-(4-
chlorophenyl)-3-methylbutanoic acid ((+)-CPA) 
Racemic (±)-2-(4-chlorophenyl)-3-methylbutanoic acid ((±)-CPA) was resolved using an 
adaption of a previously reported method.2 Briefly, racemic 2-(4-chlorophenyl)-3-
methylbutanoic acid ((±)-CPA) was resolved by crystallization with (S)-(−)-α-1-
phenylethylamine ((-)-PEA) from 20% aqueous n-propanol. The obtained salt was 
recrystallized twice from aqueous n-propanol, the enantiomerically enriched S-(+)-CPA was 
obtained by dissolving the salt in dilute hydrochloric acid and extracting with 
dichloromethane. The organic phase was washed with brine, dried (MgSO4) and 
concentrated. The residue was refined further by repeating the procedure twice to give S-
(+)-CPA with >99% ee. The pure enantiomer R-(-)-CPA was obtained by a corresponding 
protocol. NMR spectra were in agreement with  those reported for the racemic compound 
above. 
(S)-(+)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide (S-4-CMTB) 
A mixture of (S)-(+)-CPA (31.7 mg; 0.15 mmol), N-(3-dimethylaminopropyl)-N′-
ethylcarbodiimide hydrochloride (EDC; 34.7 mg; 0.18 mmol), 1-hydroxybenzotriazole (HOBt; 
25.6 mg; 0.19 mmol), 2-aminothiazole (17.9 mg; 0.18 mmol) and triethylamine (3 drops) in 
CH2Cl2 (20 mL) was stirred under an argon atmosphere for 4 days. The reaction mixture was 
diluted with CH2Cl2, washed with dilute hydrochloric acid, saturated sodium bicarbonate 
solution and saturated brine. The organic phase was dried (MgSO4) and concentrated. The 
residue was purified by flash column chromatography (SiO2, 1:4 EtOAc/light petroleum) to 
give the title compound (19 mg; 43%, 98.1% ee) as white powder. NMR spectra were in 
agreement with  those reported for the racemic compound above. 
(R)-(-)-2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide (R-4-CMTB) 
R-4-CMTB was prepared from (R)-(-)-CPA (26.3 mg; 0.12 mmol) and 2-aminothiazole (14.9 
mg; 0.15 mmol) following the procedure described for S-4-CMTB to give the title compound 
(22.9 mg; 65%, 96.6% ee) as white powder. NMR spectra were in agreement with those 
reported for the racemic compound above. 
    
2-(4-chlorophenyl)-N-(thiazol-2-yl)ethanamide (HWD001) 
HWD001 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by reaction of (4-chlorophenyl)acetic acid with thionyl chloride followed by 2-
aminothiazole:  mp 202–207 °C (EtOH);  H (200 MHz; CDCl3) 12.56 (1 H, broad s, NH), 
7.48 (1 H, d, J 3.6, thiazole), 7.36 – 7.24 (4 H, m, chlorophenyl), 7.03 (1 H, d, J 3.6,  
                                                 
2 V. V. N. Reddy, K. Ishratullah, P. V. K. Raju, A. N. Rao, T. R. Rao, PCT Int. Appl. WO 2004/060850. 
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thiazole), 3.86 (2 H, s, -CH2);  C (50 MHz; CDCl3) 168.6 (C=O), 159.8 (thiazole C-2), 136.6 
(thiazole CH-4), 133.9 (aromatic C), 131.8 (aromatic C), 130.9 (aromatic CH×2), 129.3 
(aromatic CH×2), 114.3 (thiazole CH-5), 42.3 (-CH2);  m/z (EI) 252 (M+ 35Cl, 69%), 152 
(82%), 125 (99%), 100 (100%);  (found: C, 52.17; H, 3.47; N, 11.34. C11H9ClN2OS requires 
52.28; H 3.59; N 11.08%). 
 
(rac)-2-(4-chlorophenyl)-N-(thiazol-2-yl)propanamide (HWD002) 
HWD002 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by reaction of (rac)-2-(4-chlorophenyl)propanoic acid with thionyl chloride 
followed by 2-aminothiazole:  mp 195-198 °C (EtOH);  H (200 MHz; CDCl3) 11.92 (1 H, 
broad s, NH), 7.46 (1 H, d, J 3.6, thiazole), 7.32 – 7.21 (4 H, m, chlorophenyl), 7.06 (1 H, d, J 
3.6, thiazole), 3.85 (1 H, q, J 7.1, -CH), 1.63 (3 H, d, J 7.1, Me);  C (50 MHz; CDCl3) 172.0 
(C=O), 160.0 (thiazole C-2), 138.4 (aromatic C), 136.6 (thiazole CH-4), 133.6 (aromatic C), 
129.2 (aromatic CH×2), 128.9 (aromatic CH×2), 114.2 (thiazole CH-5), 46.2 (-CH), 19.0 
(Me);  m/z (EI) 266 (M+ 35Cl, 81%), 166 (86%), 139 (100%);  (found: C, 53.78; H, 4.18; N, 
10.36. C12H11ClN2OS requires 54.03; H, 4.16; N, 10.50%). 
 
(rac)-2-(4-chlorophenyl)-N-(thiazol-2-yl)butanamide (HWD003) 
HWD003 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by alkylation of (4-chlorophenyl)acetic acid with ethyl iodide and conversion of 
the resulting carboxylic acid into the acid chloride followed by reaction with 2-aminothiazole:  
mp 180–182 °C (EtOH);  H (200 MHz; CDCl3) 10.88 (1 H, broad s, NH), 7.45 (1 H, d, J 3.7, 
thiazole), 7.31 – 7.20 (4 H, m, chlorophenyl), 7.01 (1 H, d, J 3.5, thiazole), 3.50 (1 H, t, J 7.6, 
-CH), 2.31 – 2.13 (1 H, m), 1.95 – 1.77 (1 H, m), 0.91 (3 H, t, J 7.3, Me);  C (50 MHz; 
CDCl3) 171.5 (C=O), 159.7 (thiazole C-2), 137.0 (aromatic C), 136.6 (thiazole CH-4), 133.7 
(aromatic C), 129.4 (aromatic CH×2), 129.2 (aromatic CH×2), 114.2 (thiazole CH-5), 54.2 
(-CH), 27.0 (CH2), 12.4 (Me);  m/z (EI) 280 (M+ 35Cl, 69%), 180 (85%), 153 (83%);  (found: 
C, 55.44; H, 4.65; N, 9.78. C13H13ClN2OS requires 55.61; H, 4.67; N, 9.98%). 
 
(rac)-2-(4-chlorophenyl)-N-(thiazol-2-yl)pentanamide (HWD004) 
HWD004 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by alkylation of (4-chlorophenyl)acetic acid with propyl iodide and conversion of 
the resulting carboxylic acid into the acid chloride followed by reaction with 2-aminothiazole:  
mp 127–131 °C (EtOH);  H (200 MHz; CDCl3) 12.26 (1 H, broad s, NH), 7.51 (1 H, d, J 3.7, 
thiazole), 7.29 – 7.19 (4 H, m, chlorophenyl), 7.07 (1 H, d, J 3.7, thiazole), 3.65 (1 H, t, J 7.6, 
-CH), 2.28 – 2.08 (1 H, m, CHHCH2CH3), 1.93 – 1.74 (1 H, m, CHHCH2CH3), 1.42 – 1.14 (2 
H, m, CH2CH2CH3), 0.91 (3 H, t, J 7.2, CH2CH2CH3);  C (50 MHz; CDCl3) 171.7 (C=O), 
160.2 (thiazole C-2), 137.3 (aromatic C), 136.4 (thiazole CH-4), 133.6 (aromatic C), 129.2 
(aromatic CH×2), 129.1 (aromatic CH×2), 114.2 (thiazole CH-5), 52.2 (-CH), 35.9 (CH2), 
21.0 (CH2), 14.0 (Me);  m/z (EI) 294 (M+ 35Cl, 73%), 194 (83%), 167 (68%), 100 (78%);   
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(found: C, 57.18; H, 5.21; N, 9.67. C14H15ClN2OS requires 57.04; H, 5.13; N, 9.50%). 
 
(rac)-2-(4-chlorophenyl)-N-(thiazol-2-yl)hexanamide (HWD005) 
HWD005 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by alkylation of (4-chlorophenyl)acetic acid with butyl iodide and conversion of 
the resulting carboxylic acid into the acid chloride followed by reaction with 2-aminothiazole:  
mp 141–145 °C (EtOH);  H (200 MHz; CDCl3) 11.30 (1 H, broad s, NH), 7.49 (1 H, d, J 3.7, 
thiazole), 7.32 – 7.21 (4 H, m, chlorophenyl), 7.05 (1 H, d, J 3.6, thiazole), 3.60 (1 H, t, J 7.6, 
-CH), 2.32 – 2.08 (1 H, m, -CHCHH), 1.96 – 1.75 (1 H, m, -CHCHH), 1.43 – 1.12 (2 H, 
m, CH2CH2CH3), 0.86 (3 H, t, J 6.9, Me);  C (50 MHz; CDCl3) 171.7 (C=O), 160.0 (thiazole 
C-2), 137.3 (aromatic C), 136.5 (thiazole CH-4), 133.6 (aromatic C), 129.3 (aromatic CH×2), 
129.2 (aromatic CH×2), 114.2 (thiazole CH-5), 52.5 (-CH), 33.5 (CH2), 29.9 (CH2), 22.6 
(CH2), 14.0 (Me);  m/z (EI) 308 (M+ 35Cl, 89%), 208 (84%), 125 (100%);  (found: C, 58.18; H, 
5.53; N, 9.17. C15H17ClN2OS requires C, 58.34; H, 5.55; N, 9.07%). 
 
(rac)-2-(4-chlorophenyl)-N-(thiazol-2-yl)heptanamide (HWD006) 
HWD006 was prepared as a white powder following the procedure described for preparation 
of 4-CMTB by alkylation of (4-chlorophenyl)acetic acid with pentyl iodide and conversion of 
the resulting carboxylic acid into the acid chloride followed by reaction with 2-aminothiazole:  
mp 107–111 °C (EtOH);  H (200 MHz; CDCl3) 11.82 (1 H, broad s, NH), 7.49 (1 H, d, J 3.6, 
thiazole), 7.31 – 7.17 (4 H, m, chlorophenyl), 7.04 (1 H, d, J 3.6, thiazole), 3.60 (1 H, t, J 7.6, 
-CH), 2.31 – 2.05 (1 H, m, -CHCHH), 1.96 – 1.71 (1 H, m, -CHCHH), 1.37 – 1.11 (2 H, 
m, CH2CH2CH3), 0.82 (3 H, app. t, J 6.0, Me);  C (50 MHz; CDCl3) 171.6 (C=O), 159.9 
(thiazole C-2), 137.3 (aromatic C), 136.6 (thiazole CH-4), 133.7 (aromatic C), 129.4 
(aromatic CH×2), 129.2 (aromatic CH×2), 114.3 (thiazole CH-5), 52.6 (-CH), 33.8 (CH2), 
31.7 (CH2), 27.5 (CH2), 22.6 (CH2), 14.3 (Me);  m/z (EI) 322 (M+ 35Cl, 81%), 222 (82%);  
(found: C, 59.31; H, 5.87; N, 8.56. C16H19ClN2OS requires C, 59.52; H, 5.93; N, 8.86%). 
 
2-(4-chlorophenyl)-2-methyl-N-(thiazol-2-yl)propanamide (HWD007) 
HWD007 was prepared as a white powder following the general procedures described for 
preparation of 4-CMTB but commencing with alkylation of 2-(4-chlorophenyl)propanoic acid 
with methyl iodide to afford 2-(4-chlorophenyl)-2-methylpropanoic acid; the latter was 
converted into the acid chloride by reaction with thionyl chloride and then into the title 
compound by subsequent reaction with 2-aminothiazole:  mp 193–196 °C (EtOAc/light 
petroleum);  H (200 MHz; CDCl3) 8.45 (1 H, broad s, NH), 7.39 – 7.25 (5 H, m, thiazole & 
chlorophenyl), 6.96 (1 H, d, J 3.4, thiazole), 1.66 (6 H, s, Me×2);  C (50 MHz; CDCl3) 174.6 
(C=O), 158.3 (thiazole C-2), 141.8 (aromatic C), 137.5 (thiazole CH-4), 133.9 (aromatic C), 
129.4 (aromatic CH×2), 127.9 (aromatic CH×2), 114.0 (thiazole CH-5), 47.2 (-C), 26.8 
(Me×2);  m/z (EI) 280 (M+ 35Cl, 36%), 153 (100%);  (found: C, 55.01; H, 4.66; 10.11. 
C13H13ClN2OS requires C, 55.61; H, 4.67; N, 9.98%). 
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2-butyl-2-(4-chlorophenyl)-N-(thiazol-2-yl)hexanamide (HWD008) 
HWD008 was prepared as a white powder following the general procedures described for 
preparation of 4-CMTB but commencing with alkylation of 2-(4-chlorophenyl)hexanoic acid 
with butyl iodide to afford 2-butyl-2-(4-chlorophenyl)hexanoic acid; the latter was converted 
into the acid chloride by reaction with thionyl chloride and then into the title compound by 
subsequent reaction with 2-aminothiazole:  mp 146–149 °C (EtOAc/light petroleum);  H (200 
MHz; CDCl3) 8.44 (1 H, broad s, NH), 7.35 – 7.18 (5 H, m, thiazole & chlorophenyl), 6.96 (1 
H, d, J 3.6, thiazole), 2.10 – 1.95 (4 H, m), 1.40 – 1.17 (4 H, m), 1.17 – 0.93 (4 H, m), 0.86 (6 
H, t, J 7.2, Me×2);  C (50 MHz; CDCl3) 174.0 (C=O), 158.4 (thiazole C-2), 140.6 (aromatic 
C), 137.6 (thiazole CH-4), 133.6 (aromatic C), 129.2 (aromatic CH×2), 128.6 (aromatic 
CH×2), 113.8 (thiazole CH-5), 54.1 (-C), 34.6 (CH2×2), 26.0 (CH2×2), 23.2 (CH2×2), 14.1 
(Me×2);  m/z (EI) 364 (M+ 35Cl, 72%), 237 (97%), 127 (100%);  (found: C, 62.49; H, 6.94; N, 
7.61. C19H25ClN2OS requires C, 62.53; H, 6.90; N, 7.68%). 
 
(rac)-2-(4-chlorophenyl)-3-methyl-N-(pyridin-3-yl)butanamide (HWD009) 
Following the procedures described for preparation of 4-CMTB, (rac)-2-(4-chlorophenyl)-3-
methylbutanoic acid was converted into its acid chloride derivative and reacted with pyridin-
3-amine to afford HWD009 as a white powder:  mp 170–173 °C (CHCl3/light petroleum);  H 
(200 MHz; CDCl3) 8.48 (1 H, d, J 2.5, pyridine ring H-2), 8.32 (1 H, dd, J 1.4 and 4.7, 
pyridine ring H-6), 8.25 (1 H, ddd, J 1.4, 2.5 and 8.4, pyridine ring H-4), 7.47 (1 H, broad s, 
NH), 7.34 – 7.29 (4 H, m, chlorophenyl CH), 7.23 (1 H, dd, J 4.8 and 8.4, pyridine ring H-5), 
3.00 (1 H, d, J 10.1, -CH), 2.45 (1 H, double septet, J 10.1 and 6.5, isopropyl CH), 1.10 (3 
H, d, J 6.5, Me), 0.74 (3 H, d, J 6.6, Me);  C (50 MHz; CDCl3) 172.5 (C=O), 144.5 (pyridine 
CH), 141.0 (pyridine CH), 137.0 (C), 135.5 (C), 133.5 (C), 129.5 (chlorophenyl CH×2), 128.5 
(chlorophenyl CH×2), 127.8 (pyridine CH), 124.0 (pyridine CH), 61.7 (-CH), 32.0 (isopropyl 
CH), 21.5 (Me), 20.5 (Me);  m/z (EI) 288 (M+ 35Cl, 24%), 246 (37%), 167 (51%), 125 (99%). 
 
(rac)-2-(4-chlorophenyl)-3-methyl-N-(pyridin-2-yl)butanamide (HWD011) 
Following the procedures described for preparation of 4-CMTB, (rac)-2-(4-chlorophenyl)-3-
methylbutanoic acid was converted into its acid chloride derivative and reacted with pyridin-
2-amine to afford HWD011 as a white powder:  mp 130–133 °C (light petroleum);  H (200 
MHz; CDCl3) 8.98 (1 H, broad s, NH), 8.30 – 8.21 (2 H, m, pyridine ring H-3 and H-6), 7.80 
(1 H, ddd, J 1.9, 7.5 and 8.5, pyridine ring H-4), 7.28 – 7.18 (4 H, m, chlorophenyl CH), 7.07 
(1 H, ddd, J 1.1, 4.9 and 7.3, pyridine ring H-5), 2.93 (1 H, d, J 10.4, -CH), 2.45 (1 H, 
double septet, J 10.3 and 6.5, isopropyl CH), 1.05 (3 H, d, J 6.5, Me), 0.68 (3 H, d, J 6.6, 
Me);  C (50 MHz; CDCl3) 171.5 (C=O), 151.5 (pyridine ring C-2), 147.0 (pyridine ring CH-6), 
138.0 (pyridine ring CH-4), 136.5 (chlorophenyl C), 132.5 (chlorophenyl C), 128.5 
(chlorophenyl CH×2), 128.0 (chlorophenyl CH×2), 119.5 (pyridine ring CH-5), 114.0 (pyridine 
ring CH-3), 61.2 (-CH), 31.0 (isopropyl CH), 21.0 (Me), 20.0 (Me);  m/z (EI) 288 (M+ 35Cl, 
36%), 273 (100%), 167 (9%), 125 (44%);  (found: C, 66.56; H, 6.07; N, 9.70. C16H17ClN2O  
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requires C, 66.55; H, 5.93; N, 9.70%). 
 
(rac)-2-(4-chlorophenyl)-3-methyl-N-(pyridin-4-yl)butanamide (HWD012) 
Following the procedures described for preparation of 4-CMTB, (rac)-2-(4-chlorophenyl)-3-
methylbutanoic acid was converted into its acid chloride derivative and reacted with pyridin-
4-amine to afford HWD012 as a white powder:  mp 164–167 °C (CHCl3/light petroleum);  H 
(200 MHz; CDCl3) 8.40 (2 H, ~dd, J 4.9 and 1.5, pyridine ring CH×2), 7.94 (1 H, broad s, 
NH), 7.40 (2 H, ~dd, J 4.9 and 1.5, pyridine ring CH×2), 7.31 – 7.28 (4 H, m, chlorophenyl 
CH), 3.01 (1 H, d, J 10.1, -CH), 2.45 (1 H, double septet, J 10.1 and 6.5, isopropyl CH), 
1.09 (3 H, d, J 6.5, Me), 0.72 (3 H, d, J 6.6, Me);  C (50 MHz; CDCl3) 172.5 (C=O), 151.0 
(pyridine CH-2/6), 145.5 (pyridine ring C-4), 137.0 (chlorophenyl C), 133.7 (chlorophenyl C), 
130.5 (chlorophenyl CH×2), 129.5 (chlorophenyl CH×2), 114.5 (pyridine CH-3/5), 62.5 (-
CH), 32.0 (isopropyl CH), 22.0 (Me), 20.5 (Me);  m/z (EI) 288 (M+ 35Cl, 40%), 246 (54%), 167 
(78%), 125 (83%). 
 
(rac)-2-(4-chlorophenyl)-N,3-dimethyl-N-(thiazol-2-yl)butanamide (HWD013) 
To an ice-cooled suspension of NaH (60% w/w dispersion in mineral oil; 0.34 g, 8.5 mmol) in 
DMF (20 mL) was added 2-(4-chlorophenyl)-3-methyl-N-(thiazol-2-yl)butanamide (0.54 g, 1.8 
mmol). After 20 minutes, methyl iodide (0.82 mL, 13 mmol) was added dropwise to the 
resulting mixture. The mixture was then left stirring overnight at ambient temperature. DMF 
was removed using cold finger apparatus and the solid residue partitioned between EtOAc 
(55 mL) and saturated NaCl solution (50 mL). The organic layer collected was dried 
(Na2SO4) and evaporated to dryness. The crude product thus obtained was purified by flash 
column chromatography (CH2Cl2) and crystallised (hexane) to afford product the title 
compound (0.26 g; 46%) as a white powder:  mp 101–104 °C;  H (200 MHz; CDCl3) 7.48 (1 
H, d, J 3.6, thiazole), 7.27 (4 H, app. s, chlorophenyl), 6.99 (1 H, d, J 3.6, thiazole), 3.73 (3 
H, s, N-Me), 3.58 (1 H, d, J 10.1, -CH), 2.56 (1 H, double septet, J 10.1 and 6.5, isopropyl 
CH), 1.04 (3 H, d, J 6.5, Me), 0.73 (3 H, d, J 6.6, Me);  C (50 MHz; CDCl3) 172.4 (C=O), 
160.3 (thiazole C-2), 137.0 (thiazole CH-4), 136.0 (chlorophenyl C), 133.6 (chlorophenyl C), 
130.0 (chlorophenyl CH×2), 129.2 (chlorophenyl CH×2), 115.2 (thiazole CH-5), 57.6 (-CH), 
35.0 (N-Me), 32.7 (isopropyl CH), 22.2 (Me), 20.3 (Me). 
